Featured Tickers:
Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in PROCEPT BioRobotics Corporation, LeMaitre Vascular or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how PROCEPT BioRobotics Corporation, LeMaitre Vascular and Inc. compare based on key financial metrics to determine which better meets your investment needs.
About PROCEPT BioRobotics Corporation, LeMaitre Vascular and Inc.
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Latest Health Care Equipment & Supplies and PROCEPT BioRobotics Corporation, LeMaitre Vascular, Inc. Stock News
As of April 23, 2025, PROCEPT BioRobotics Corporation had a $3.1 billion market capitalization, compared to the Health Care Equipment & Supplies median of $241.3 million. PROCEPT BioRobotics Corporation’s stock is down 34.5% in 2025, down 0.2% in the previous five trading days and up 10.98% in the past year.
Currently, PROCEPT BioRobotics Corporation does not have a price-earnings ratio. PROCEPT BioRobotics Corporation’s trailing 12-month revenue is $224.5 million with a -40.7% net profit margin. Year-over-year quarterly sales growth most recently was 56.4%. Analysts expect adjusted earnings to reach $-1.518 per share for the current fiscal year. PROCEPT BioRobotics Corporation does not currently pay a dividend.
As of April 23, 2025, LeMaitre Vascular, Inc. had a $2.0 billion market cap, putting it in the 60th percentile of all stocks. LeMaitre Vascular, Inc.’s stock is down 0.3% in 2025, up 8.4% in the previous five trading days and up 41.54% in the past year.
Currently, LeMaitre Vascular, Inc.’s price-earnings ratio is 46.4. LeMaitre Vascular, Inc.’s trailing 12-month revenue is $219.9 million with a 20.0% net profit margin. Year-over-year quarterly sales growth most recently was 13.9%. Analysts expect adjusted earnings to reach $2.237 per share for the current fiscal year. LeMaitre Vascular, Inc. currently has a 0.9% dividend yield.
How We Compare PROCEPT BioRobotics Corporation, LeMaitre Vascular and Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at PROCEPT BioRobotics Corporation, LeMaitre Vascular and Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions